Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05255666
Title Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cynthia Ma
Indications
Therapies
Age Groups: adult | senior
Covered Countries


No variant requirements are available.